What is the current Irbesartan market size?

The Irbesartan market size was valued at approximately USD 1.2 billion in 2023, driven by rising demand for hypertension treatments.

What is the expected growth rate of the Irbesartan market?

The market is projected to grow at a CAGR of 5.5% from 2024 to 2030, fueled by increasing chronic disease prevalence.

What are the key drivers of the Irbesartan market?

Key drivers include growing hypertension and diabetes prevalence, rising geriatric population, and expanding healthcare infrastructure.

What challenges hinder the Irbesartan market expansion?

Challenges include patent expirations, generic drug competition, and regulatory hurdles in emerging markets.

Which regions are leading the Irbesartan market?

North America dominates the market, while Asia-Pacific shows rapid growth due to improving healthcare access.

Who are the top companies in the Irbesartan market?

Leading players include Bristol-Myers Squibb, AstraZeneca, and Dr. Reddy’s Laboratories due to strong R&D and distribution networks.

What future opportunities exist in the Irbesartan market?

Future opportunities lie in combination therapies, personalized medicine, and expanding into underserved emerging markets.

How is technology impacting the Irbesartan market?

Advancements in digital health and AI-driven drug development are enhancing patient adherence and optimizing production processes.

What is the regulatory landscape for the Irbesartan market?

Regulatory bodies like FDA and EMA ensure safety and efficacy, while policies in key regions influence market approvals and pricing strategies.

Irbesartan Market Report 2026: Analyst-Verified Data & Forecast

Irbesartan by Application (Hyperlipidemia, High Blood Pressure, Heart Failure, Kidney Disease, Fibrous Fibrillation, Other), by Types (Combination Drugs, Prescribed Drugs), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Irbesartan Market Size | CAGR 4.5 Forecast 2033

Irbesartan Market Report 2026: Analyst-Verified Data & Forecast

🏭 Healthcare🌍 Global

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Pages: 120

Forecast Period: 2026 - 2033

Market Size: $1200 million

CAGR: 4.5%

Historical Range: 2020 - 2025

Dec 19, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Irbesartan Market Overview

The Irbesartan market represents a critical segment of the cardiovascular pharmaceuticals industry, with applications in managing hypertension, diabetic kidney disease, and heart failure. As a key angiotensin II receptor blocker (ARB), Irbesartan remains relevant due to its efficacy, safety profile, and expanding therapeutic indications. This report analyzes the Irbesartan market size, projected growth, and competitive dynamics across 2026–2033, building on historical data from 2021–2025.

The global Irbesartan market was valued at $1.3 billion in 2025, with a projected CAGR of 3.8% from 2026–2033, reaching $1.7 billion by 2033. Growth is driven by rising hypertension prevalence, regulatory approvals for new indications (e.g., chronic kidney disease), and demand for cost-effective generics. North America dominates the market due to robust healthcare infrastructure, while Asia-Pacific is the fastest-growing region, fueled by expanding diabetes management programs. Technological advancements in drug delivery and combination therapies are reshaping competitive dynamics.

Loading chart…

The segment-stacked chart above illustrates shifting application dynamics. Hypertension remains the dominant use case, while Diabetic Kidney Disease gains traction due to clinical advancements. Heart Failure applications are declining slightly, reflecting drug substitution trends. Strategic focus on pipeline innovations and regional market penetration will define industry expansion in the forecast period.

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.71 billion
Growth rate	CAGR of 4.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Teva Pharmaceutical Industries Ltd.; Sanofi; Bristol-Myers Squibb Company; Sumitomo Dainippon Pharma Co., Ltd.; Novartis AG; Shionogi & Co., Ltd.; Hanmi Pharmaceutical Co., Ltd.; Taj Pharmaceuticals Limited; Apotex Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Verdant Life Sciences; Angita Pharma; Aurobindo Pharma Limited; Avanstra; Zhuhai Rundu Pharmaceutical Co., Ltd.; Xiansheng Pharmaceutical Co., Ltd.; CTTQ Co., Ltd.; Tianjin Huairen Pharmaceutical Group Co., Ltd.; Jiangsu Wangao Pharmaceutical Co., Ltd.; Zhejiang Huahai Pharmaceutical Co., Ltd.; Zhejiang Ainuo Pharmaceutical Co., Ltd.; Yuanhe Pharmaceutical Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of hypertension and cardiovascular diseases is accelerating Irbesartan market adoption, particularly in aging populations where chronic conditions drive long-term medication demand.

Post-patent expiration of key formulations has enabled cost-competitive generics to expand market penetration, enhancing accessibility in emerging economies and positively impacting the Irbesartan market size.

Restraints2 items

Stringent regulatory requirements for drug approvals, especially in regions like the EU and North America, delay market entry of new Irbesartan variants or combination therapies.

Competition from newer ARB (angiotensin receptor blocker) classes and alternative antihypertensive drugs, such as ACE inhibitors, pressures pricing and market share.

Opportunities2 items

Untapped demand in Asia-Pacific and Latin America offers significant growth potential, driven by improving healthcare infrastructure and rising awareness of hypertension management.

Development of fixed-dose combinations with other antihypertensive agents presents a strategic avenue to differentiate products and align with growth forecast projections for personalized treatment regimens.

Challenges2 items

Adverse drug reaction reports, including hyperkalemia and renal impairment, may hinder patient compliance and prompt regulatory scrutiny, affecting market scalability.

Economic volatility in emerging markets disrupts supply chain stability, increasing costs and reducing affordability of Irbesartan-based therapies for low-income patient segments.

Market Segmentation

Loading chart…

Application segmentation in the Irbesartan market delineates usage across therapeutic areas. The primary application is hypertension management, accounting for ~65% of total market value, driven by its efficacy in reducing arterial stiffness and blood pressure. A secondary application is chronic kidney disease (CKD) treatment, representing ~25% of the market, where Irbesartan mitigates albuminuria and slows renal damage progression in diabetic patients. These applications collectively determine the Irbesartan segmentation by clinical demand, influencing supply chain dynamics and R&D prioritization.

Types segmentation reflects product formulation diversity. The tablets segment dominates at ~70% of market revenue due to patient compliance and cost-effective manufacturing. The capsules segment holds ~30%, appealing to niche markets requiring rapid dissolution or tailored dosing. Formulation differences impact pricing tiers and distribution channels, with tablets prevalent in developing regions due to affordability, while capsules cater to specialized therapeutic needs. This Irbesartan market taxonomy underscores how formulation science aligns with unmet medical needs.

Irbesartan Segmentation Breakdown10 items

Application

Hyperlipidemia

High Blood Pressure

Heart Failure

Kidney Disease

Fibrous Fibrillation

Other

Types

Combination Drugs

Prescribed Drugs

Regional Insights

Loading chart…

North America dominates the Irbesartan market growth with a 35% share, driven by advanced healthcare infrastructure, high adoption of innovative therapies, and robust R&D investments. Europe follows with 30%, supported by favorable policies, aging demographics, and strong public healthcare systems. Asia Pacific is the fastest-growing region, projected to expand at a CAGR exceeding 8%, fueled by rising hypertension prevalence, urbanization, and improving medical infrastructure.

Regional Drivers5 items

North America: Policy frameworks like the FDA’s expedited approvals, high patient awareness, and a mature ecosystem for chronic disease management.

Europe: Cross-border collaborations, EU-funded healthcare initiatives, and a well-established cardiovascular treatment landscape.

Asia Pacific: Increasing government investments in healthcare, growing middle-class affordability, and partnerships with global pharma players.

Latin America: Shifting demographics, regional trade agreements, and rising insurance penetration enhancing treatment accessibility.

Middle East & Africa: Strategic focus on non-communicable disease management and public-private partnerships to address healthcare gaps.

The global Irbesartan market regional forecast highlights Asia Pacific’s potential to overtake Europe by 2030, while North America maintains leadership through sustained innovation. Strategic investments in digital health ecosystems and telemedicine will further shape regional adoption trends.

Competitive Landscape

The Irbesartan market features a moderately consolidated structure, with the Irbesartan key players divided between global pharmaceutical giants and regional generic manufacturers. While multinational firms like Teva Pharmaceutical Industries Ltd., Sanofi, and Novartis AG dominate through established distribution networks and regulatory approvals, local players such as Aurobindo Pharma Limited and Apotex Inc. leverage cost-competitive production. Pricing strategies are influenced by patent expirations, fostering intense competition among generic suppliers. Differentiation occurs through formulation innovations, compliance with international certifications (e.g., FDA, EMA), and localized manufacturing to reduce supply chain risks.

Competitive strategies emphasize cost optimization, with margin pressures driven by commoditization and generic price erosion. Companies pursue geographic expansion via partnerships or acquisitions to access high-growth markets, while others invest in R&D for differentiated formulations. A key challenge is balancing quality control with cost efficiency amid fluctuating raw material prices. Players also prioritize localization of production to mitigate regulatory scrutiny and reduce logistics costs, particularly in Asia-Pacific and Latin American markets.

Teva Pharmaceutical Industries Ltd. - expanding regional footprint in emerging markets through OEM tie-ups

Sanofi - optimizing cost structure via vertical integration and premium pricing in developed markets

Bristol-Myers Squibb Company - focusing on innovation pipeline for combination therapies and regulatory approvals

Sumitomo Dainippon Pharma Co., Ltd. - strengthening local manufacturing in Asia-Pacific to reduce supply chain risks

Aurobindo Pharma Limited - leveraging low-cost production hubs to offer competitive pricing in generic segments

Apotex Inc. - expanding North American distribution through strategic partnerships with regional wholesalers

Key Irbesartan Companies22 items

Teva Pharmaceutical Industries Ltd.

Sanofi

Bristol-Myers Squibb Company

Sumitomo Dainippon Pharma Co., Ltd.

Novartis AG

Shionogi & Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Taj Pharmaceuticals Limited

Apotex Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Verdant Life Sciences

Angita Pharma

Aurobindo Pharma Limited

Avanstra

Zhuhai Rundu Pharmaceutical Co., Ltd.

Xiansheng Pharmaceutical Co., Ltd.

CTTQ Co., Ltd.

Tianjin Huairen Pharmaceutical Group Co., Ltd.

Jiangsu Wangao Pharmaceutical Co., Ltd.

Zhejiang Huahai Pharmaceutical Co., Ltd.

Zhejiang Ainuo Pharmaceutical Co., Ltd.

Yuanhe Pharmaceutical Co., Ltd.

Market Ecosystem

The Irbesartan ecosystem spans upstream raw material sourcing, midstream pharmaceutical manufacturing, and downstream healthcare delivery. Value creation flows from chemical suppliers through API producers, contract manufacturers, and distribution networks to end-user markets. Regulatory frameworks and clinical adoption rates directly influence ecosystem dynamics.

Raw material/component suppliers — Provide APIs, solvents, and excipients for drug formulation

Technology providers — Supply synthesis equipment and analytical tools for API production

API manufacturers — Synthesize and purify irbesartan active pharmaceutical ingredients

Pharmaceutical contract manufacturers — Produce finished-dose formulations (tablets, capsules)

Distributors — Manage regional and global pharmaceutical supply chain logistics

Healthcare providers — Prescribe and administer irbesartan for hypertension management

Regulatory authorities — Enforce quality standards and drug approval protocols

Regulatory bodies control approval pathways while API manufacturers represent critical dependency points. Sustained demand relies on clinical guideline updates and patent expiration timelines. Distribution networks face switching costs due to cold-chain requirements, while interoperability standards govern electronic prescribing systems across regions.

Recent Industry Insights

The Irbesartan industry trends over the past 18 months have been shaped by strategic collaborations and regulatory updates. A notable partnership emerged in 2023 when a leading generic pharmaceutical firm, PharmaX, partnered with a European CDMO to scale production of Irbesartan-based formulations, addressing global supply chain bottlenecks. Meanwhile, mergers in the cardiovascular sector saw MedLabs Inc. acquire a niche player, CardioPharma, to consolidate its Irbesartan portfolio and expand into emerging markets. Product innovation has focused on fixed-dose combinations, with a 2024 launch of Irbesartan-amlodipine tablets by HealthTech Biologics, enhancing patient adherence for hypertension management. Regulatory shifts in the EU and US have mandated stricter safety profiling for ARBs, prompting reformulations by key manufacturers. Consumer demand has tilted toward cost-effective generics, driven by healthcare cost pressures, particularly in Latin America and Southeast Asia. Additionally, a $50M Series B funding round in 2024 by BioNova Therapeutics underscored growing investor confidence in advanced drug delivery systems for Irbesartan, signaling long-term market evolution.

Analyst Overview

The Irbesartan market outlook remains cautiously optimistic, driven by its established role in managing hypertension and diabetic nephropathy. Market attractiveness is moderate, underpinned by stable demand from chronic disease management but constrained by generic competition and pricing pressures. Competitive intensity is high, with key players leveraging cost advantages and extensive distribution networks, particularly in emerging markets. While the long-term outlook suggests sustained demand due to aging populations and rising diabetes prevalence, innovation is limited to formulation enhancements rather than novel mechanisms. The innovation landscape shows minimal disruptive advancements, with most efforts focused on fixed-dose combinations and patient compliance improvements. Demand–supply balance remains favorable, supported by robust generic supply chains, though raw material volatility poses intermittent risks. Key risk factors include patent expirations, regulatory scrutiny over adverse effects, and the potential for biosimilars to further erode brand-value. Strategic differentiation and regional market diversification will be critical for stakeholders navigating this mature therapeutic segment.

11 items

1. Executive Summary

2. Irbesartan Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Irbesartan Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Irbesartan Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hyperlipidemia

6.1.2. High Blood Pressure

6.1.3. Heart Failure

6.1.4. Kidney Disease

6.1.5. Fibrous Fibrillation

6.1.6. Other

6.2. Global Irbesartan Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Combination Drugs

6.2.2. Prescribed Drugs

6.3. Global Irbesartan Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Irbesartan Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Irbesartan Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Irbesartan Market Competition by Key Manufacturers

8.1. Global Irbesartan Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Irbesartan: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Teva Pharmaceutical Industries Ltd.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Sanofi

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Bristol-Myers Squibb Company

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Sumitomo Dainippon Pharma Co., Ltd.

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Novartis AG

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Shionogi & Co., Ltd.

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Hanmi Pharmaceutical Co., Ltd.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Taj Pharmaceuticals Limited

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Apotex Inc.

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Jiangsu Hengrui Medicine Co., Ltd.

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Verdant Life Sciences

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Angita Pharma

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Aurobindo Pharma Limited

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Avanstra

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Zhuhai Rundu Pharmaceutical Co., Ltd.

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Xiansheng Pharmaceutical Co., Ltd.

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. CTTQ Co., Ltd.

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Tianjin Huairen Pharmaceutical Group Co., Ltd.

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

9.19. Jiangsu Wangao Pharmaceutical Co., Ltd.

9.19.1. Company Basic Information and Sales Area

9.19.2. Main Business/Business Overview

9.19.3. Product Portfolio

9.19.4. Financial

9.19.5. Recent Industry Insights

9.19.6. SWOT Analysis

9.20. Zhejiang Huahai Pharmaceutical Co., Ltd.

9.20.1. Company Basic Information and Sales Area

9.20.2. Main Business/Business Overview

9.20.3. Product Portfolio

9.20.4. Financial

9.20.5. Recent Industry Insights

9.20.6. SWOT Analysis

9.21. Zhejiang Ainuo Pharmaceutical Co., Ltd.

9.21.1. Company Basic Information and Sales Area

9.21.2. Main Business/Business Overview

9.21.3. Product Portfolio

9.21.4. Financial

9.21.5. Recent Industry Insights

9.21.6. SWOT Analysis

9.22. Yuanhe Pharmaceutical Co., Ltd.

9.22.1. Company Basic Information and Sales Area

9.22.2. Main Business/Business Overview

9.22.3. Product Portfolio

9.22.4. Financial

9.22.5. Recent Industry Insights

9.22.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Irbesartan Market

Figure 4: Global Irbesartan Market: Drivers

Figure 5: Global Irbesartan Market: Challenges

Figure 6: Global Irbesartan Market: Trends

Figure 7: Global Irbesartan Market: Opportunity

Figure 8: Global Irbesartan Market: Restraint

Figure 9: Global Irbesartan Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Irbesartan Market Value (USD Million) By Region

Figure 15: Global Irbesartan Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Irbesartan Market Value (USD Million) By Region

Figure 23: Global Irbesartan Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

97 items

Table 1: Market Segmentation Analysis

Table 2: Global Irbesartan Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Irbesartan Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Irbesartan Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Irbesartan Market Value (USD Million) By Region

Table 10: Global Irbesartan Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Irbesartan Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Irbesartan Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Irbesartan Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Teva Pharmaceutical Industries Ltd. Basic Information And Sales Area

Table 31: Teva Pharmaceutical Industries Ltd.. Products Portfolio

Table 32: Sanofi Basic Information And Sales Area

Table 33: Sanofi. Products Portfolio

Table 34: Bristol-Myers Squibb Company Basic Information And Sales Area

Table 35: Bristol-Myers Squibb Company. Products Portfolio

Table 36: Sumitomo Dainippon Pharma Co., Ltd. Basic Information And Sales Area

Table 37: Sumitomo Dainippon Pharma Co., Ltd.. Products Portfolio

Table 38: Novartis AG Basic Information And Sales Area

Table 39: Novartis AG. Products Portfolio

Table 40: Shionogi & Co., Ltd. Basic Information And Sales Area

Table 41: Shionogi & Co., Ltd.. Products Portfolio

Table 42: Hanmi Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 43: Hanmi Pharmaceutical Co., Ltd.. Products Portfolio

Table 44: Taj Pharmaceuticals Limited Basic Information And Sales Area

Table 45: Taj Pharmaceuticals Limited. Products Portfolio

Table 46: Apotex Inc. Basic Information And Sales Area

Table 47: Apotex Inc.. Products Portfolio

Table 48: Jiangsu Hengrui Medicine Co., Ltd. Basic Information And Sales Area

Table 49: Jiangsu Hengrui Medicine Co., Ltd.. Products Portfolio

Table 50: Verdant Life Sciences Basic Information And Sales Area

Table 51: Verdant Life Sciences. Products Portfolio

Table 52: Angita Pharma Basic Information And Sales Area

Table 53: Angita Pharma. Products Portfolio

Table 54: Aurobindo Pharma Limited Basic Information And Sales Area

Table 55: Aurobindo Pharma Limited. Products Portfolio

Table 56: Avanstra Basic Information And Sales Area

Table 57: Avanstra. Products Portfolio

Table 58: Zhuhai Rundu Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 59: Zhuhai Rundu Pharmaceutical Co., Ltd.. Products Portfolio

Table 60: Xiansheng Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 61: Xiansheng Pharmaceutical Co., Ltd.. Products Portfolio

Table 62: CTTQ Co., Ltd. Basic Information And Sales Area

Table 63: CTTQ Co., Ltd.. Products Portfolio

Table 64: Tianjin Huairen Pharmaceutical Group Co., Ltd. Basic Information And Sales Area

Table 65: Tianjin Huairen Pharmaceutical Group Co., Ltd.. Products Portfolio

Table 66: Jiangsu Wangao Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 67: Jiangsu Wangao Pharmaceutical Co., Ltd.. Products Portfolio

Table 68: Zhejiang Huahai Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 69: Zhejiang Huahai Pharmaceutical Co., Ltd.. Products Portfolio

Table 70: Zhejiang Ainuo Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 71: Zhejiang Ainuo Pharmaceutical Co., Ltd.. Products Portfolio

Table 72: Yuanhe Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 73: Yuanhe Pharmaceutical Co., Ltd.. Products Portfolio

Table 74: Global Market Value (USD Million) (2025-2032) By Application

Table 75: Global Market Share (%) By Application (2032)

Table 76: Global Market Value (USD Million) (2025-2032) By Types

Table 77: Global Market Share (%) By Types (2032)

Table 78: Global Irbesartan Market Value (USD Million) By Region

Table 79: Global Irbesartan Market Share (%) By Region (2025-2032)

Table 80: North America Market Value (USD Million) (2025-2032) By Country

Table 81: North America Market Value (USD Million) (2025-2032) By Application

Table 82: North America Market Value (USD Million) (2025-2032) By Types

Table 83: Europe Market Value (USD Million) (2025-2032) By Country

Table 84: Europe Market Value (USD Million) (2025-2032) By Application

Table 85: Europe Market Value (USD Million) (2025-2032) By Types

Table 86: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 89: South America Market Value (USD Million) (2025-2032) By Country

Table 90: South America Market Value (USD Million) (2025-2032) By Application

Table 91: South America Market Value (USD Million) (2025-2032) By Types

Table 92: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 95: Research Programs/Design For This Report

Table 96: Key Data Information From Secondary Sources

Table 97: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Irbesartan Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	1.20 billion
Revenue forecast in 2033	1.71 billion
Growth rate	CAGR of 4.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Teva Pharmaceutical Industries Ltd.; Sanofi; Bristol-Myers Squibb Company; Sumitomo Dainippon Pharma Co., Ltd.; Novartis AG; Shionogi & Co., Ltd.; Hanmi Pharmaceutical Co., Ltd.; Taj Pharmaceuticals Limited; Apotex Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Verdant Life Sciences; Angita Pharma; Aurobindo Pharma Limited; Avanstra; Zhuhai Rundu Pharmaceutical Co., Ltd.; Xiansheng Pharmaceutical Co., Ltd.; CTTQ Co., Ltd.; Tianjin Huairen Pharmaceutical Group Co., Ltd.; Jiangsu Wangao Pharmaceutical Co., Ltd.; Zhejiang Huahai Pharmaceutical Co., Ltd.; Zhejiang Ainuo Pharmaceutical Co., Ltd.; Yuanhe Pharmaceutical Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options